(AP Photo/Julia Weeks)

Pfiz­er's Paxlovid gets March FDA ad­vi­so­ry meet­ing to dis­cuss full ap­proval

Pfiz­er’s an­tivi­ral drug for Covid-19 is look­ing to inch clos­er to full FDA ap­proval, with an agency ad­vi­so­ry com­mit­tee sched­uled for March.

The meet­ing is go­ing to be held on March 16 from 9 a.m. to 5 p.m. EST, ac­cord­ing to a doc­u­ment in the fed­er­al reg­is­ter from the US De­part­ment of Health and Hu­man Ser­vices. The meet­ing will fo­cus on whether Paxlovid should be ap­proved to treat mild-to-mod­er­ate Covid-19 in adults who are at high risk for the virus’ pro­gres­sion to a se­vere case which can lead to hos­pi­tal­iza­tion or death.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.